GSE196076
Dnase1l3 enhances antitumor immunity and suppresses tumor progression [bulk RNAseq]
For the chronic inflammation-related colon cancer model (AOM/DSS-colon cancer model), 3-month-old Dnase1l3 WT and KO mice were injected with AOM (8 mg/kg, body weight). One week later, mice were challenged with 2.5% DSS water for 7 days followed by a 14-day recovery with regular drinking water for three cycles. Body weight, rectal bleeding and diarrhea were monitored during the entire experiment. Mice with more than 25% weight loss were removed during the experiment. For the AOM model, 2-month-old Dnase1l3 WT and KO mice were injected intraperitoneally with AOM (8 mg/kg, body weight). Colon tissues were isolated 9 hours, or five days after injection. All animal experiments were conducted in accordance with guidelines of NIEHS/NIH Animal Care and Use Committee. Overall design: RNA was extracted from the whole colon tissue of Dnase1l3 WT and KO mice at basal condition, after one cycle of AOM/DSS, after three cycles of AOM/DSS and from final tumors from Dnase1l3 WT and KO mice after the three cycles of AOM/DSS. For each group, three to five samples were used. Comparisons were carried out between the two genotypes for each group. RNA was extracted using RNeasy mini kit (QIAGEN) and were of sufficient quality.